Skip to main content

Table 4 Clinical study results for stem cell therapy

From: Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review

Study

Patient reported outcomes

Progression

Lesion volume

Hip survivorship

 

Outcome

    

Hernigou et al. [35]

HHS (13 years)

Improved compared to baseline score (88 vs 70)^

 

Decreased lesion volume (12 cm3 vs 26 cm3)^

17.6% conversion rate to THA at 13 years follow up

Wang et al. [9]

HHS

Improved compared to baseline score (83.7 ± 10.34 vs 71.2 ± 6.56)*

23.7% rate of progression to higher ARCO class

 

11.8% conversion to THA at 27.6 months

Gangji et al. [2]

Lequesne index

Improved compared to CD (SC group 4.8 ± 1.8, CD group NR)*

Decreased progression (23.1% vs 72.7%)*

Decreased lesion volume at 24 months (SC group volume decreased 42%, CD group volume decreased 1%)*, no improvement at 60 months (SC group volume decreased 42%, CD group volume decreased 22%)#

No improvement in hip survivorship (57.2 months vs 50.2 months)

 

VAS pain

Improved compared to CD (SC group 20.8 ± 7.7, CD group NR)*

   
 

WOMAC

No improvement compared to CD (raw score NR)

   

Sen et al. [14]

HHS (12 months)

Improved compared to CD (83.65 ± 8.04 vs 76.68 ± 13.86)*

  

Improved hip survivorship (51.85 ± 0.15 weeks vs. 46.62 ± 2.34 weeks)*

Zhao et al. [8]

HHS ARCO 1C,2B,2C (60 months)

Improved compared to CD (raw score NR)*

Decreased progression (3.8% vs. 22.7%)*

Decreased lesion volume in ARCO 2B (6.5% vs 13.3% of FH), and ARCO 2C (13.8% vs 29.3%)*

Decreased rate of conversion to THA/vascularized bone graft in the SC group compared to CD (3.7% vs. 22.7%)*

  1. HHS = Harris Hip Score, ARCO = Association Research Circulation Osseous classification, VAS = visual analog scale pain score, WOMAC = Western Ontario and McMaster Universities Osteoarthritis index, ^ = no statistics reported, * = p < 0.05, # = p = 0.06, CD = core decompression, NR = not reported, FH = femoral head, THA = total hip arthroplasty.